Baseline characteristics. Values are n (%) unless otherwise specified.
| Characteristics, n = 29 | Values |
|---|---|
| HLA-B27–positive | 21 (72) |
| Male | 19 (66) |
| Symptom duration, yrs, mean ± SD | 5 ± 2.1 |
| Fulfilled ASAS clinical criteria | 17 (59) |
| Fulfilled ASAS imaging criteria | 12 (41) |
| SpA features, ≥ 2 | 25 (86) |
| Uveitis | 3 (10) |
| Psoriasis | 9 (31) |
| IBD | 0 |
| Regular NSAID | 13 (45) |
| Baseline outcome measures, mean ± SD | |
| BASDAI | 4.8 ± 0.7 |
| Back pain score | 5.7 ± 1 |
| BASFI | 3.5 ± 0.7 |
| ASDAS | 2.5 ± 0.3 |
| CRP | 2.7 ± 1.7 |
| Raised CRP | 8 (29) |
ASAS: Assessment of Spondyloarthritis international Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; CRP: C-reactive protein; IBD: inflammatory bowel disease; NSAID: nonsteroidal antiinflammatory drugs; SpA: spondyloarthritis.